Legato Capital Management’s Analog Devices ADI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.05M Sell
10,205
-9,560
-48% -$3.78M 0.34% 65
2026
Q1
$6.29M Buy
19,765
+1,100
+6% +$350K 0.57% 23
2025
Q4
$5.06M Sell
18,665
-4,000
-18% -$1M 0.44% 34
2025
Q3
$5.57M Hold
22,665
0.61% 26
2025
Q2
$5.39M Buy
22,665
+22
+0.1% +$4.58K 0.64% 24
2025
Q1
$4.57M Buy
22,643
+7,587
+50% +$1.64M 0.62% 24
2024
Q4
$3.2M Sell
15,056
-8,048
-35% -$1.78M 0.42% 37
2024
Q3
$5.32M Hold
23,104
0.66% 16
2024
Q2
$5.27M Sell
23,104
-5,561
-19% -$1.19M 0.71% 14
2024
Q1
$5.67M Hold
28,665
0.68% 16
2023
Q4
$5.69M Hold
28,665
0.74% 13
2023
Q3
$5.02M Buy
28,665
+399
+1% +$73.6K 0.73% 13
2023
Q2
$5.51M Sell
28,266
-3,529
-11% -$654K 0.74% 10
2023
Q1
$6.27M Buy
31,795
+124
+0.4% +$22.2K 1.14% 4
2022
Q4
$5.19M Buy
+31,671
New +$4.94M 0.99% 5

Other funds holding ADI

Legato Capital Management's ADI Position: Q2 2026 in Review

Legato Capital Management reduced its Analog Devices (ADI) stake by 48% in Q2 2026, selling an estimated $3.78M and leaving 10,205 shares worth $4.05M. The position accounts for 0.34% of the portfolio, ranked #65.

Legato Capital Management first reported a position in ADI in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.29M in Q1 2026. 2,270 funds tracked by Wall St. Rank hold ADI as of Q2 2026.

  • Legato Capital Management held 10,205 shares of Analog Devices worth $4.05M as of Q2 2026.
  • Legato Capital Management sold 9,560 Analog Devices shares in Q2 2026, an estimated $3.78M.
  • Analog Devices made up 0.34% of Legato Capital Management's portfolio in Q2 2026, its #65 holding.
  • Legato Capital Management first reported a position in Analog Devices in Q4 2022 and has held it in 15 quarters since.
  • Legato Capital Management's Analog Devices position peaked at $6.29M in Q1 2026.
  • 2,270 funds tracked by Wall St. Rank held Analog Devices as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.